MetLife, Inc. filings document the regulatory record of a Delaware financial services company with NYSE-listed common stock and preferred securities, including depositary shares tied to Series E and Series F preferred stock. Recent Form 8-K reports furnish earnings releases, quarterly financial supplements, total assets under management fact sheets and Regulation FD disclosures related to variable investment income.
The filings also cover capital-structure actions such as subordinated debenture issuance and preferred stock dividend declarations. Proxy materials describe board composition, committee assignments, executive compensation and shareholder voting matters, while material-event reports record governance changes and other corporate disclosures.
MetLife, Inc. reported a routine director equity compensation transaction. A non-management director acquired 639 shares of MetLife common stock on 01/02/2026 at $80.32 per share as part of the standard director retainer paid in stock. Following this transaction, the director beneficially owned 2,108 shares directly.
The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors, meaning the stock represents compensation that is being deferred rather than an open-market purchase.
MetLife, Inc. disclosed that one of its non-management directors received additional common stock as part of regular board compensation. On 01/02/2026, the director acquired 639 shares of MetLife common stock at a stated price of $0 per share, reflecting stock paid in lieu of a portion of cash retainer fees. Following this transaction, the director beneficially owns 33,990 shares of MetLife common stock in direct ownership. The filing notes that MetLife’s non-management director compensation arrangements provide that a portion of director retainer fees is paid in MetLife common stock.
MetLife, Inc. director Carlos M. Gutierrez reported receiving additional common stock as part of non-management director compensation. On 01/02/2026, he acquired 639 shares of MetLife common stock at a price of $0 per share, reflecting payment of a portion of his retainer fees in stock rather than cash. Following this transaction, he beneficially owns 25,024 shares directly and 18,807 shares indirectly through the Carlos M. Gutierrez Trust.
METLIFE, INC. reported that one of its directors acquired common stock as part of standard non-management director compensation. On 01/02/2026, the director received 639 shares of MetLife common stock at a price of $80.32 per share, recorded as an acquisition. After this transaction, the director beneficially owned 9,721 shares of MetLife common stock in direct ownership.
A portion of non-management director retainer fees is paid in MetLife common stock, and the director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. The filing is made by one reporting person in the capacity of a director.
MetLife, Inc. disclosed that one of its non-management directors acquired 639 shares of MetLife common stock on 01/02/2026 at a price of $80.32 per share. This transaction was reported as an acquisition related to the director's compensation.
After this transaction, the director beneficially owns 23,562 shares of MetLife common stock in direct ownership. The filing explains that MetLife's non-management director compensation includes payment of part of retainer fees in MetLife common stock, and the director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
MetLife, Inc. reported that one of its non-management directors acquired 1,105 shares of MetLife common stock on 01/02/2026 at a price of $80.32 per share. This was part of the standard director compensation program, under which portions of board and board chair retainers are paid in MetLife common stock rather than cash.
The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this transaction, the director beneficially owns 103,859 shares of MetLife common stock in direct ownership.
MetLife, Inc. reported a routine insider equity transaction involving one of its non-management directors. On 01/02/2026, the director received 639 shares of MetLife common stock as part of non-management director retainer fees, at a price of $80.32 per share. After this award, the director beneficially owned 4,931 shares of MetLife common stock held directly.
The filing notes that MetLife’s compensation arrangements pay a portion of non-management director fees in company stock, and the director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. This reflects standard equity-based compensation rather than an open-market purchase or sale.
MetLife, Inc. reported that its institutional investment arm, MetLife Investment Management, has closed the acquisition of PineBridge Investments, LLC and certain related affiliates. This step makes PineBridge part of MetLife’s investment management platform as of December 30, 2025.
On the same date, MetLife also released a fact sheet showing the pro forma combined total assets under management for MetLife Investment Management and PineBridge, as if the acquisition had been completed on September 30, 2025. The news release and the pro forma combined AUM fact sheet are provided as exhibits, giving investors more detail on how the combined investment management businesses will look following the transaction.
MetLife, Inc. is providing an early look at certain 2025 results and its capital deployment plans. For the quarter ending December 31, 2025, it estimates variable investment income of approximately $385 million to $435 million (pre-tax), compared with a quarterly target of $425 million (pre-tax) based on full-year 2025 guidance of about $1.7 billion (pre-tax). For full year 2025, MetLife anticipates a 7.7% return on its private equity portfolio and plans to use an assumed 9% annual return in its 2026 outlook, contributing to an estimated $1.6 billion (pre-tax) of variable investment income in 2026.
The company expects to deploy about $4 billion of capital in 2025 to support organic growth and approximately $1 billion for merger and acquisition activity, including funding for the expected closing of its previously announced PineBridge Investments acquisition. Total common stock repurchases for 2025 are expected to be about $2.85 billion, including roughly $430 million in the fourth quarter, with a similar repurchase level anticipated in 2026. All figures are preliminary, unaudited and subject to change as year-end closing procedures are completed.
A MetLife-related account filed a notice of proposed sale of 68 shares of common stock, to be sold through Bernstein Institutional Services LLC on the NYSE. The shares have an indicated aggregate market value of $5,556.28, while the filing notes that 658,891,656 common shares are outstanding. The seller acquired these 68 shares by purchase from Deutsche Bank on June 28, 2013, with cash payment on July 3, 2013. The notice also lists several small common stock sales by various MetLife separate accounts and retirement plans over the prior three months, each showing the number of shares sold and gross proceeds. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer.